[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].

doi:10.3760/cma.j.cn501113-20190606-00199

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Use of sofosbuvir-based regimens in the treatment of adolescents and children with chronic hepatitis C].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 20 Jan 2021

He S, Wang X Y, Han Q Y, Liu Z W

Abstract excerpt

Sofosbuvir has ushered in a new era of hepatitis C treatment with its strong inhibition on the replication of hepatitis C virus, favorable safety profile and less interactions with other drugs. Sofosbuvir-based regimens have been included as the first-line therapies for the treatment of adults with chronic hepatitis C (CHC) in international guidelines. Available clinical trial data show that sofosbuvir with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Sofosbuvir
Share to Antiviral Agents
Share to China
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Ribavirin

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 33548971
DOI: 10.3760/cma.j.cn501113-20190606-00199
PMCID: PMC12814277

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.